CA2369058A1 - Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes - Google Patents

Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes Download PDF

Info

Publication number
CA2369058A1
CA2369058A1 CA002369058A CA2369058A CA2369058A1 CA 2369058 A1 CA2369058 A1 CA 2369058A1 CA 002369058 A CA002369058 A CA 002369058A CA 2369058 A CA2369058 A CA 2369058A CA 2369058 A1 CA2369058 A1 CA 2369058A1
Authority
CA
Canada
Prior art keywords
gene
protein
retroviral
integrase
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369058A
Other languages
English (en)
Inventor
Zeger Debyser
Erik De Clercq
Peter Cherepanov
Wim Pluymers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369058A1 publication Critical patent/CA2369058A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un gène synthétique ou une région de gène ayant une utilisation améliorée de codon par rapport au gène de type de sauvage et servant à l'expression de niveau élevé d'une protéine rétrovirale dans des cellules eucariotes, la protéine rétrovirale exprimée possédant une activité enzymatique dans la cellule eucariote. L'invention concerne également un gène synthétique ou une région de gène codant une enzyme rétrovirale ou une partie d'enzyme exprimée normalement dans une cellule mammalienne ou dans une autre cellule eucariote, au moins un codon non préféré dans le gène de type sauvage codant l'enzyme ayant été remplacé par un codon préféré codant le même acide aminé. La protéine rétrovirale peut être une protéase, une transcriptase inverse, une protéine intégrase ou son précurseur gag-pol de polyprotéine. Dans un mode de réalisation la protéine rétrovirale à activité enzymatique est une protéine lentivirale. Dans d'autres modes de réalisation, la protéine à activité enzymatique est une enzyme pol. Dans des modes de réalisation préférés, la protéine à activité enzymatique est une intégrase lentivirale, ou, mieux, une enzyme de VIH; dans d'autres modes de réalisation, la protéine à activité enzymatique est idéalement une intégrase de VIH. L'invention concerne également un procédé de détection de l'intégrase intracellulaire au moyen d'un gène reporter démuni de promoteur.
CA002369058A 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes Abandoned CA2369058A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99201306 1999-04-26
EP99201306.0 1999-04-26
EP00200171.7 2000-01-18
EP00200171 2000-01-18
PCT/EP2000/003765 WO2000065076A2 (fr) 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes

Publications (1)

Publication Number Publication Date
CA2369058A1 true CA2369058A1 (fr) 2000-11-02

Family

ID=26071747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369058A Abandoned CA2369058A1 (fr) 1999-04-26 2000-04-26 Gene synthetique destine a l'expression d'une proteine retrovirale active dans les eucariotes

Country Status (11)

Country Link
EP (1) EP1183381A2 (fr)
JP (1) JP2002542791A (fr)
AU (1) AU778106B2 (fr)
BR (1) BR0010077A (fr)
CA (1) CA2369058A1 (fr)
HU (1) HUP0201019A2 (fr)
IL (1) IL146090A0 (fr)
NO (1) NO20015168L (fr)
PL (1) PL351988A1 (fr)
RU (1) RU2001131728A (fr)
WO (1) WO2000065076A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
CA2358385C (fr) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
DE60042702D1 (de) * 1999-12-23 2009-09-17 Us Gov Health & Human Serv Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
AUPQ580300A0 (en) * 2000-02-23 2000-03-16 National Cancer Centre Of Singapore Pte Ltd Genetic analysis
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1411770A4 (fr) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
DE602004030104D1 (de) * 2003-05-06 2010-12-30 Nat Inst Of Advanced Ind Scien System zur bestimmung der aktivität mehrerer gentranskriptionen
ATE521629T1 (de) 2005-10-07 2011-09-15 Angeletti P Ist Richerche Bio Matrixmetalloproteinase-11-impfstoff
JP6824594B2 (ja) 2014-09-11 2021-02-03 Jnc株式会社 合成遺伝子の設計方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
US5811270A (en) * 1994-05-20 1998-09-22 Grandgenett; Duane P. In vitro method for concerted integration of donor DNA molecules using retroviral integrase proteins
US6200811B1 (en) * 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
IL131131A0 (en) * 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
EP1141313A2 (fr) * 1998-12-31 2001-10-10 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
CA2358385C (fr) * 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations

Also Published As

Publication number Publication date
JP2002542791A (ja) 2002-12-17
EP1183381A2 (fr) 2002-03-06
PL351988A1 (en) 2003-07-14
AU4557900A (en) 2000-11-10
AU778106B2 (en) 2004-11-18
NO20015168L (no) 2001-12-14
WO2000065076A3 (fr) 2001-12-13
IL146090A0 (en) 2002-07-25
NO20015168D0 (no) 2001-10-23
WO2000065076A2 (fr) 2000-11-02
HUP0201019A2 (en) 2002-08-28
RU2001131728A (ru) 2004-02-20
BR0010077A (pt) 2002-01-15

Similar Documents

Publication Publication Date Title
US5994136A (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
US7311907B2 (en) Lentiviral packaging cells
Cherepanov et al. High‐level expression of active HIV‐1 integrase from a synthetic gene in human cells
AU2018336042A1 (en) Retroviral vectors
EP1244797B1 (fr) Systeme de vecteurs trans-lentiviral
AU778106B2 (en) Synthetic gene for expressing active retroviral protein in eukaryotes
CA2408786C (fr) Vecteurs retroviraux comportant une structure renforcee de terminaison de transcription 3'
AU773015B2 (en) Lentiviral vectors
WO2001004360A9 (fr) Bioanalyses de recombinaison retrovirale et utilisations
US20230151388A1 (en) Modified vectors for production of retrovirus
US20120034693A1 (en) Recombinant vector and use in gene therapy

Legal Events

Date Code Title Description
FZDE Discontinued